Cerevel Therapeutics Holdings, Inc. (CERE)

Market Cap	5.34B
Revenue (ttm)	n/a
Net Income (ttm)	-317.76M
Shares Out	156.32M
EPS (ttm)	-2.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	510,718
Open	34.54
Previous Close	34.55
Day's Range	34.05 - 35.26
52-Week Range	19.86 - 41.46
Beta	1.47
Analysts	Buy
Price Target	41.63 (+21.9%)
Earnings Date	Feb 27, 2023

About CERE

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a sel...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 285
• Stock Exchange: NASDAQ
• Ticker Symbol: CERE

Analyst Forecast

According to 18 analysts, the average rating for CERE stock is "Buy." The 12-month stock price forecast is $41.63, which is an increase of 21.90% from the latest price.

Price Target

$41.63

(21.90% upside)

Analyst Consensus: Buy